PCI Begins Move-In Phase at Newly-Expanded Bridgend Site

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-06-08-2017, Volume 12, Issue 6

The new storage and distribution facility provides PCI with additional space, complementing its existing footprint currently used for specialist clinical-trial logistics as well as packaging, labeling, and qualified person activities for investigational medicinal products.

PCI Clinical Services, a full-service provider of outsourced pharmaceutical services, announced on May 15, 2017 that a move-in phase has begun following the practical completion of its expanded Clinical Services Center of Excellence at Bridgend, United Kingdom. The new storage and distribution facility will provide substantial additional space, complementing PCI’s existing footprint currently used for specialist clinical-trial logistics as well as packaging, labeling, and qualified person activities for investigational medicinal products.

Works on the new development at 2500 Central Park, Bridgend Industrial Estate began in 2016. PCI collected the keys on April 17, 2017. Internal fit-out works are currently underway, with full completion scheduled for September 2017. The facility is set to be validated and operational by January 2018.

Bridgend is one of PCI’s seven facilities supporting medicines distributed to more than 100 countries around the world. PCI has been a tenant on the Central Park estate since 2007, occupying 11,000 square feet at Biotec House. Steady investment and growth have enabled the company to expand five years later into a custom-built 22,000 square feet space in neighboring units. 

The latest addition to PCI’s Clinical Services Center of Excellence provides a modern, high-spec unit with warehouse and office space across two floors, purpose built to support PCI’s specialist secondary packaging, storage, and logistical needs. It also provides scope for further expansion in the future. Once the facility is fully operational, PCI will be able to expand its services in supporting temperature-sensitive therapies, including cold chain and ultra cold chain, at temperatures ranging from controlled ambient 15–25 °C, 2–8 °C, down to -20 °C, -30 °C, -40 °C, -60 °C, and -90 °C, including liquid nitrogen vapor phase storage below -150 °C for advanced therapeutic medicinal products (ATMPs), as well as bespoke refrigerated and frozen temperatures according to client needs. 

Source: PCI Clinical Services